AnaptysBio (ANAB) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AnaptysBio (ANAB) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 76.6% versus a loss of 24.6%. Over five years, ANAB leads with a +124.8% price change compared with -83.3% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.39 billion), about 1.0 times the size, while AnaptysBio is growing revenue faster (+157.0% vs +15.6%).
On valuation, AnaptysBio trades at a lower forward P/E (8.7x vs 8.9x for Sarepta Therapeutics). AnaptysBio converts more of its revenue into profit, with a net margin of -5.6% versus -32.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | SRPT |
|---|---|---|
| Share price | $46.63 | $13.33 |
| Market cap | $1.39B | $1.43B |
| 1-day change | -1.62% | -5.93% |
| YTD return | +44.28% | -38.06% |
| 1-year return | +76.58% | -24.65% |
| 5-year return | +124.76% | -83.26% |
| P/E ratio (TTM) | 7.15 | 666.50 |
| Forward P/E | 8.66 | 8.87 |
| EPS (TTM) | $6.52 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $234.60M | $2.20B |
| Revenue growth (YoY) | +157.01% | +15.58% |
| Net income (latest FY) | $-13.23M | $-713.41M |
| Gross margin | — | 98.84% |
| Operating margin | 96.72% | -31.83% |
| Net margin | -5.64% | -32.45% |
| 52-week high | $72.36 | $24.68 |
| 52-week low | $26.01 | $13.25 |
| Distance from 52-week high | -35.56% | -45.99% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +87.11% | +63.32% |
| Average volume | 496.92K | 2.70M |
| Shares outstanding | 29.73M | 107.24M |
| Employees | — | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed SRPT by 101.2 percentage points over the past year.
- Sarepta Therapeutics trades at a higher earnings multiple (666.5x vs 7.2x trailing P/E).
- AnaptysBio is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -32.5 cents for Sarepta Therapeutics.
- AnaptysBio grew revenue faster in its latest fiscal year (+157.01% vs +15.58%).
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
ANAB vs SRPT FAQ
Which is bigger, AnaptysBio or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.39B for AnaptysBio (ANAB).
Which stock has performed better over the past year, ANAB or SRPT?
ANAB returned +76.58% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ANAB or SRPT?
ANAB has the lower trailing P/E at 7.2, versus 666.5 for SRPT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are AnaptysBio and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.